XVIVO Q3: A negative FX surprise despite excellent organic growth - Redeye
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Aktieanalys

XVIVO Q3: A negative FX surprise despite excellent organic growth - Redeye

{newsItem.title}

XVIVO delivers a Q3 that aligns with our expectations but is below market expectations due to FX headwind. The increased disposable capacity contributed to 54% growth of Thoracic disposables (62% for the whole Thoracic business based on CER), the service offer is subject to improvements, and Abdominal disposables had a modest quarter at 13% organic growth. On the positive side, we note that machine sales are high, so we are suggesting additional support in the future. The organic growth (CER) was 41%, which is a positive surprise even if actual sales were below market expectations and the FX headwind was higher than expected at 6% vs the expected -2%.

Länk till analysen i sin helhet: https://www.redeye.se/research/1045613/xvivo-q3-a-negative-fx-surprise-despite-excellent-organic-growth?utm_source=finwire&utm_medium=RSS

Nyheter om Xvivo Perfusion

Läses av andra just nu

Om aktien Xvivo Perfusion

Senaste nytt